SCHEMBL13495358

SCHEMBL13495358

CON1C(=O)c2cccc3c(O)ccc(c23)C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.55
MEN1 O00255 9/20 0.55
USP2 O75604 7/20 0.55
MAPT P10636 7/20 0.55
KEAP1 Q14145 5/20 0.55
NFE2L2 Q16236 5/20 0.55
LMNA P02545 3/20 0.55
RECQL P46063 3/20 0.55
ATM Q13315 3/20 0.55
HTT P42858 2/20 0.55
RGS12 O14924 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
POLB P06746 5/20 0.51
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 3/20 0.51
PABPC1 P11940 1/20 0.51
XBP1 P17861 1/20 0.51
NFKB1 P19838 1/20 0.51
SMARCA2 P51531 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11245313 0.82 KMT2A (0.56) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL9006289 0.81 KMT2A (0.65) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL13496107 0.81 KMT2A (0.49) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL13495353 0.81 CYP1B1 (0.63) KMT2AMEN1MAPTLMNANPC1
SCHEMBL13495346 0.81 PRMT1 (0.74) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL13495361 0.79 PRMT1 (0.48) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL10701883 0.78 KMT2A (0.59) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL9006354 0.77 MEN1 (0.68) KMT2AMEN1USP2MAPTKEAP1
SCHEMBL12540917 0.76 NPC1 (0.42) KMT2AMEN1MAPTLMNARECQL
SCHEMBL13495357 0.76 MEN1 (0.68) KMT2AMEN1MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC KMT2A 219/4885MEN1 98/4885USP2 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.